REFERENCES
- Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and so-cial development. Lancet. 2010; 375 (9728): 1814–29.
- Barry C.E. 3rd, H.I. Boshoff, V. Dartois, T. Dick, S. Ehrt, J. Flynn, et al. The spectrum of latent tuberculosis: rethinking the biology and interven-tion strategies. Nat Rev Microbiol. 2009; 7 (12): 845–55.
- Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol. 2001; 55: 139–63.
- Wayne, L.G., and L.G. Hayes. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non-replicating persistence. Infect Immun. 1996; 64 (6): 2062–9
- Frothingharrl, R., J.E. Stout, and C.D. Hamilton. Current issues in global tuberculosis control. Int J Infect Dis. 2005; 9 (6): 297–311.
- Iona, E., F. Giannoni, M. Pardini, L. Brunori, G. Orefici, and L. Fattorini. Metronidazole plus rifampin sterilizes long-term dormant Mycobac-terium tuberculosis. Antimicrob Agents Chemother. 2007; 51 (4): 1537–40.
- Filippini P, Iona E, Piccaro G, Peyron P, Neyrolles O, Fattorini L. Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010; 54 (6): 2712–5.
- Sacchettini, J.C., E.J. Rubin, and J.S. Freundlich. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol. 2008; 6 (1): 41–52.
- Barry CE 3rd, Boshoff H.I, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des. 2004; 10 (26): 3239-62.
- Kurt O, Girginkarde§ler N, Balcio§lu IC, Ozbilgin A, Ok UZ. A comparison of metronidazole and single-dose ornidazole for the treatment of di-entamoebiasis. Clin Microbiol Infect. 2008; 14 (6): 601–4.
- Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections. J Med Chem. 1996; 39 (3): 673–679.
- Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman pri-mates. Infect Immun. 2008; 76 (6): 2333–40.
- National Institute of Allergy and Infectious Diseases. Metronidazole for Pulmonary Tuberculosis (South Korea). http://clinicaltrials.gov/ct 2/show/ NCT00425113
- Tetko I, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, et al. Virtual computational chemistry laboratory - design and description. J Comput Aid Mol Des. 2005;19 (6): 453–63
- Kim P, Kang S, Boshoff HI, Jiricek J, Collins M, Singh R, et al. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J Med Chem. 2009; 52 (5): 1329-44.
- Iseman MD. Tuberculosis chemotherapy, including directly observed chemotherapy. In: A Clinician's Guide to Tuberculosis. 2000; 271-321. Lip-pincott Williams & Wilkins.